In a report released today, Daina Graybosch from Leerink Partners maintained a Buy rating on Bolt Biotherapeutics (BOLT), with a price target of $33.00. The company’s shares closed last Friday at $18.79, close to its 52-week low of $17.30.
According to TipRanks.com, Graybosch is a 3-star analyst with an average return of 13.2% and a 45.5% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Silverback Therapeutics, Molecular Partners AG, and Nektar Therapeutics.
Currently, the analyst consensus on Bolt Biotherapeutics is a Strong Buy with an average price target of $39.25, representing a 120.5% upside. In a report issued on May 14, Stifel Nicolaus also maintained a Buy rating on the stock with a $37.00 price target.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
